Business Context and Reporting Period
Company: IMPACT BIOMEDICAL INC.
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2025
Event: Entry into a Material Definitive Agreement (Debt Conversion Agreement).
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The primary financial data relates to a specific debt settlement:
- Original Debt Instrument: Revolving promissory note dated March 31, 2023, with an original amount of $12,000,000.
- Debt Settlement: Full and final satisfaction of the outstanding debt balance and related obligations.
- Consideration Paid: Issuance of 31,939,778 shares of freely tradeable common stock ($0.001 par value).
- Interest Rate History: Previously amended to WSJ Prime + 0.5%.
Material Changes
The Company has materially altered its capital structure and liability profile through the following actions:
- Debt Elimination: The outstanding balance of the Original Note and all amendments are extinguished.
- Equity Dilution: The Company issued approximately 31.94 million shares to the lender (DSS, Inc.) in exchange for debt forgiveness.
- Scope of Settlement: The agreement covers the Original Note, all amendments, and any additional financial or operational support provided by the Lender between June 21, 2025, and the transaction closing date.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates a strategic move to convert debt to equity to settle obligations with DSS, Inc. No forward-looking guidance regarding revenue or earnings is provided in this document.
Risks and Contingencies:
- Dilution Risk: The issuance of 31,939,778 shares represents a significant increase in the share count, which may dilute existing shareholders.
- Transaction Finality: The settlement is contingent upon the closing of the transaction as defined in the Debt Conversion Agreement (Exhibit 10.1).
Investor Verification Checklist
- Verify the exact closing date of the transaction to confirm the final share issuance date.
- Review the full text of the Debt Conversion Agreement (Exhibit 10.1) for any covenants or conditions precedent not summarized in the 8-K.
- Confirm the total outstanding share count post-issuance to assess the percentage of dilution.
- Check for any remaining liabilities to DSS, Inc. or its affiliates that may not have been covered by the "full and final satisfaction" clause.